Strategic Focus Target neurology and neurodegenerative disease portfolios with ATH434 as a disease-modifying oral candidate addressing Parkinsonian disorders, highlighting strong relevance to biotech and pharma buyers seeking innovative CNS therapeutics.

Clinical Progress Leverage recent positive regulatory feedback from the FDA and upcoming Phase 3 plans for ATH434 in Multiple System Atrophy to engage potential CROs, trial sites, and contract research teams involved in late-stage neurodegenerative programs.

Strategic Partnerships Position Alterity as a partner for strategic collaborations on shared drug discovery platforms, leveraging the broad pipeline and patentable compounds to attract partners seeking early access to novel mechanisms in neurodegeneration.

Executive Access Engage with newly appointed board member and senior leadership updates to build relationships with decision-makers and advisory networks, offering opportunities for co-development discussions and advisory collaborations.

Global Footprint Capitalize on dual offices in Melbourne and San Francisco to target regional stakeholders, align with global clinical trial management partners, and tailor regional regulatory and market-access strategies for CNS therapies.